JUN and prostate cancer: The main anticancer inhibitory actions of catechins are by inducing apoptosis in different animal models, reducing the phosphorylation of c-Jun and Erk1/2 levels in lung tumorigenesis models, suppressing phospho-Akt and nuclear β-catenin levels in colon cancer models, inhibiting the insulin-like growth factor-1 (IGF1)/IGF1 receptor (IGF1R) axis in colon and prostate cancer models, and restraining the VEGF-dependent angiogenesis in lung and prostate cancer models (69–71).